March 19 (Reuters) - HLS Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FISCAL 2019 FINANCIAL RESULTS
* HLS THERAPEUTICS INC - QTRLY REVENUES $13.9 MILLION VERSUS $16.7 MILLION
* HLS THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.40
* HLS THERAPEUTICS QTRLY LOSS PER SHARE OF $0.40
* HLS THERAPEUTICS INC - RECEIVED MEDICAL DEVICE LICENSE FROM HEALTH CANADA FOR CSAN PRONTO POINT-OF-CARE BLOOD TESTING MEDICAL DEVICE
* HLS THERAPEUTICS INC - RECEIVED APPROVAL FROM HEALTH CANADA FOR VASCEPA TO REDUCE RISK OF CARDIOVASCULAR EVENTS
* HLS THERAPEUTICS - AS AT DEC 31, 2019, COMPANY HAD CASH AND CASH EQUIVALENTS OF $47.1 MILLION, UP FROM $10.9 MILLION AT DEC 31, 2018